Kezar Life Sciences Company

Based in South San Francisco, we are a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class immunoproteasome inhibitor, is currently in a Phase 1b trial, with a Phase 2 trial in lupus nephritis patients expected to initiate during the first half of 2019. Kezar is also poised to expand its development programs throughout 2019 with plans to initiate multiple Phase 2 trials of KZR-616, in up to four additional autoimmune indications, and to nominate an initial clinical candidate for the treatment of cancer from its protein secretion program.
Technology: Preventive Medicine
Industry: Precision Medicine
Headquarters: South San Francisco
Founded Date: 2015
Employees Number: Undisclosed
Funding Status: IPO

Visit Website
contact@kezarbio.com
Register and Claim Ownership